New call-to-action
New call-to-action
New call-to-action

Acadia Initiates Phase 3 COMPASS PWS Study of Carbetocin

The 12-week study will evaluate the efficacy and safety of carbetocin nasal spray in approximately 170 children aged 5 to 30 years with PWS.

Acadia Pharmaceuticals has initiated its pivotal Phase 3 COMPASS PWS study of carbetocin nasal spray (ACP-101) in the United States. COMPASS PWS is a 12-week study evaluating the efficacy and safety of carbetocin nasal spray for hyperphagia in approximately 170 children and adults aged 5 to 30 years with Prader-Willi syndrome.

At this time, about 36 clinical study sites throughout the United States, Canada, and Europe are expected to participate in the Phase 3 COMPASS PWS study. Participants who complete the Phase 3 study will be eligible to enroll in a long-term, open-label extension study designed to investigate the safety and tolerability of long-term treatment with carbetocin nasal spray.

For more information on the COMPASS PWS study, including who can participate, you can visit the trial website at The website also features a “Find a Research Site” tool which will be updated on an ongoing basis as trial sites are opened.

If you have questions about the carbetocin nasal spray Phase 3 study, you can contact Acadia at

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For almost 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at and follow us on LinkedIn and Twitter.



Susan Hedstrom


Susan Hedstrom is the Executive Director for the Foundation for Prader-Willi Research. Passionate about finding treatments for PWS, Susan joined FPWR in 2009 shortly after her son, Jayden, was diagnosed with Prader-Willi Syndrome. Rather than accepting PWS as it has been defined, Susan has chosen to work with a team of pro-active and tireless individuals to accelerate PWS research in order to change the future of PWS. Inspired by her first FPWR conference and the team of researchers that were working to find answers for the syndrome, she joined the FPWR team in 2010 and led the development of the One SMALL Step walk program. Under Susan’s leadership, over $15 million has been raised for PWS related research.